[ad_1]
Stockholm, Sweden, 14 June 2023 – MGI, an organization dedicated to constructing core instruments and expertise to steer life science, introduced the signing of a licensing settlement with Xpress Genomics, a number one Stockholm-based firm specializing in automated and scalable RNA-sequencing methods. This strategic collaboration goals to revolutionize the sector of genomics via the event of latest scalable options for deep single-cell RNA-sequencing by Xpress Genomics together with MGI’s modern automation and sequencing applied sciences.
Picture Credit score: MGI Tech Co., Ltd.
Based by Prof. Rickard Sandberg and researchers in his lab, Xpress Genomics is an organization spearheaded by CEO Dr. Christoph Ziegenhain. Their major focus lies within the improvement and provision of scalable single-cell RNA-sequencing strategies that don’t sacrifice high quality or protection. The expertise supplies distinctive sensitivity and protection throughout complete transcripts, in order that Xpress Genomics customers can carry out large-scale transcriptome-wide analyses of marker genes, transcribed genetic variation and splicing.
Picture Credit score: MGI Tech Co., Ltd.
“We’re excited to lastly unify high quality and scale with our full-length scRNA-seq options”, stated Prof. Rickard Sandberg, co-founder of Xpress Genomics. “Constructing on our long-standing expertise on this space, the developed expertise will likely be streamlined into MGI’s sequencing expertise for probably the most cost-efficient and scalable full-length scRNA-seq to this point.”
“We’re delighted to embark on this thrilling collaboration with Xpress Genomics,” stated Duncan Yu, President at MGI. “By collaborating with Xpress Genomics, we will leverage their experience in automation and scalability to push the boundaries of single-cell genomics additional. MGI is fulfilling our dedication to empowering scientists and researchers worldwide with modern, cost-effective and user-friendly instruments that facilitate advances within the {industry} and convey extra alternatives for fast progress.”
“The sector of genomics continues to evolve at a fast tempo, and single-cell RNA-sequencing represents a transformative expertise with far-reaching implications throughout varied disciplines,” stated Ming Ni, Vice President of MGI. “We purpose to assist Xpress Genomics to handle the important challenges in single-cell sequencing and develop scalable options that may unlock new potentialities in genomics analysis.”
Picture Credit score: MGI Tech Co., Ltd.
Xpress Genomics additionally opened its new laboratory facility on the Most cancers Heart Karolinska (CCK) in Sweden, outfitted with MGI’s industry-leading DNBSEQ sequencers*. This new facility will allow native collaborators and companions to get entry to Xpress Genomics’ distinctive single-cell RNA-seq options. “The newly established laboratory facility serves as an important bridge to the native analysis and diagnostic neighborhood, facilitating contemporary genomic discoveries and breakthroughs in medical developments. It’s nice to see MGI’s steady efforts in empowering native prospects and companions to meet a better mission,” stated Yong Hou, Common Supervisor of MGI Europe and Africa.
*Except in any other case knowledgeable, StandardMPS and CoolMPS sequencing reagents, and sequencers to be used with such reagents usually are not obtainable in Germany, Spain, UK, Sweden, Italy, Czech Republic, Switzerland and Hong Kong (CoolMPS is out there in Hong Kong).
*Merchandise are supplied for Analysis Use Solely. Not to be used in diagnostic procedures (besides as particularly famous)
About MGI
MGI Tech Co., Ltd. (or its associates, “MGI”), headquartered in Shenzhen, is dedicated to constructing core instruments and expertise to steer life science via clever innovation. Primarily based on its proprietary expertise, MGI focuses on analysis & improvement, manufacturing, and gross sales of sequencing devices**, reagents*, and associated merchandise to assist life science analysis, agriculture, precision drugs and healthcare. MGI’s mission is to develop and promote superior life science instruments for future healthcare. As of December 31, 2022, MGI has greater than 2,800 staff, and 36% of whom are R&D personnel. Based in 2016, MGI operates in additional than 90 international locations and areas, serving greater than 2,000 prospects. For extra info, please go to the MGI web site or join on Twitter, LinkedIn or YouTube.
[ad_2]
